DDInter195 DDInter131
Betamethasone is a long-acting corticosteroid with immunosuppressive and antiinflammatory properties. It can be used topically to manage inflammatory skin conditions such as eczema, and parenterally to manage several disease states including autoimmune disorders. Betamethasone has potent glucocorticoid activity and negligible mineralocorticoid activity.
Atezolizumab is a humanized monoclonal antibody used to prevent the interaction of PD-L1 and PD-1, removing inhibition of immune responses seen in some cancers.[A18493,L7489] This medication is reserved for patients whose tumors express PD-L1, cannot receive platinum-based chemotherapy, or whose tumors do not respond to platinum-based chemotherapy. Atezolizumab was granted FDA approval on 18 October 2016. In November 2022, the manufacturer (Genentech) voluntarily withdrew the use of atezolizumab for the treatment of urothelial carcinoma, previously approved under the FDA's Accelerated Approval Program. The rest of atezolizumab indications remain unaffected.
Betamethasone {u} (Compound) resembles {v} (Compound) Mometasone
Betamethasone {u} (Compound) resembles {v} (Compound) Fludrocortisone
Betamethasone {u} (Compound) treats {v} (Disease) allergic rhinitis
Betamethasone {u} (Compound) binds {v} (Gene) CYP3A4
Betamethasone {u} (Compound) upregulates {v} (Gene) GSPT1
Betamethasone {u} (Compound) palliates {v} (Disease) kidney cancer
Betamethasone {u} (Compound) is included by {v} (Pharmacologic Class) Corticosteroid Hormone Receptor Agonists
Betamethasone {u} (Compound) downregulates {v} (Gene) DDIT3
Betamethasone {u} (Compound) causes {v} (Side Effect) Blindness
Betamethasone {u} may cause a minor interaction that can limit clinical effects when taken with {v} Orciprenaline
Betamethasone (Compound) resembles Mometasone (Compound)
Betamethasone (Compound) resembles Fludrocortisone (Compound)
Betamethasone (Compound) treats allergic rhinitis (Disease)
Betamethasone (Compound) binds CYP3A4 (Gene)
Betamethasone (Compound) upregulates GSPT1 (Gene)
Betamethasone (Compound) palliates kidney cancer (Disease)
Betamethasone (Compound) is included by Corticosteroid Hormone Receptor Agonists (Pharmacologic Class)
Betamethasone (Compound) downregulates DDIT3 (Gene)
Betamethasone (Compound) causes Blindness (Side Effect)
Betamethasone may cause a minor interaction that can limit clinical effects when taken with Orciprenaline